Strontium 89 works by emitting beta particles, which have the ability to destroy cancer cells in the bone. When administered, it is preferentially taken up by areas of increased bone turnover, often corresponding to metastatic lesions. The beta radiation emitted by Strontium 89 causes localized cell damage, thereby alleviating pain and controlling the growth of cancer cells in the bone.
